title: Stage and tissue-specific prognostic impact of miR-182 in NSCLC.
abstract: BACKGROUND
  MicroRNA (miR)-182 is frequently upregulated in cancers, has generally been viewed as an oncogene and is possibly connected to angiogenesis. We aimed to explore what impact miR-182 has in non-small cell lung cancer (NSCLC), and more explicitly its correlation with angiogenic markers.
  
  
  METHODS
  From 335 unselected stage I to IIIA NSCLC carcinomas, duplicate tumor and tumor-associated stromal cores were collected in tissue microarray blocks (TMAs). In situ hybridization (ISH) was used to detect the expression of miR-182 in tumor cells, and immunohistochemistry (IHC) was used to detect the expression of angiogenesis related protein markers.
  
  
  RESULTS
  In univariate analyses, high tumor cell expression of miR-182 was a positive prognostic factor for patients with squamous cell carcinoma (SCC, P = 0.042) and stage II patients (P = 0.003). Also in the multivariate analysis, high tumor cell miR-182 expression was associated with a good prognosis in the same groups (SCC: HR 0.57, CI 95% 0.33-0.99, P = 0.048; stage II: HR 0.50, CI 95% 0.28-0.90, P = 0.020). We found significant correlations between miR-182 and the angiogenesis related markers FGF2, HIF2α and MMP-7.
  
  
  CONCLUSIONS
  In patients with SCC and in stage II patients, high tumor cell miR-182 expression is an independent positive prognostic factor.
authors.affiliation: Institute of Clinical Medicine, University of Tromso, Tromso, Norway. Helge.Stenvold@uit.no.
authors.forename: Helge
authors.initials: H
authors.lastname: Stenvold
authors.forename: Tom
authors.initials: T
authors.lastname: Donnem
authors.forename: Sigve
authors.initials: S
authors.lastname: Andersen
authors.forename: Samer
authors.initials: S
authors.lastname: Al-Saad
authors.forename: Lill-Tove
authors.initials: LT
authors.lastname: Busund
authors.forename: Roy M
authors.initials: RM
authors.lastname: Bremnes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000235:genetics; D015870:Gene Expression; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D008297:Male; D020783:Matrix Metalloproteinase 7 / Q000235:genetics; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors
chemical_list: D035683:MicroRNAs; C538984:Mirn182 microRNA, human; D016222:Fibroblast Growth Factor 2; D020783:Matrix Metalloproteinase 7